
    
      PRIMARY OBJECTIVES:

      I. To determine a recommended dose for the combination of a p53MVA vaccine and gemcitabine
      (gemcitabine hydrochloride) and if it is well-tolerated in patients with platinum resistant,
      p53 over expressing ovarian cancer.

      SECONDARY OBJECTIVES:

      I. To evaluate T cell immunity changes and clinical response.

      OUTLINE:

      Patients receive modified vaccinia virus ankara vaccine expressing p53 subcutaneously (SC) on
      day 15 and gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8.
      Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or
      unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30
      minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 12 months.
    
  